Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer

Table 1 Correlation of NSCLC TMA staining with clinical parameters

	COX-2 Staining Intensity (Mean ± SEM units)	p-Value	TXS Staining Intensity (Mean ± SEM units)	p-Value
Gender
(n = 124) Male	28.9 ± 3.7	0.03	81.9 ± 3.4	0.04
(n = 73) Female	36.8 ± 4.1		98.6 ± 9.6
Tumour Subtype
(n = 83) Adenocarcinoma	39.5 ± 4.9	0.02	119 ± 7	< 0.0001
(n = 92) Squamous Cell Carcinoma	25.9 ± 3.7		58.9 ± 5.5
Tumour Stage
(n = 105) Stage 1	33.1 ± 3.5		93.3 ± 7.5
(n = 43) Stage 2	35 ± 8.2	0.51	82.7 ± 9.3	0.7
(n = 43) Stage 3	26.9 ± 5		90 ± 9.7
Tumour Grade
(n = 13) Grade 1	27.4 ± 8.2	0.02	104.7 ± 21.7	0.02
(n = 106) Grade 2	38.9 ± 4.4	grade 2 vs.	98 ± 6.4	grade 2 vs.
(n = 64) Grade 3	26.9 ± 5	grade 3	70.4 ± 6.7	grade 3
Nodal Status
(n = 119) Node Negative	35 ± 3.9	0.22	91.7 ± 6.3	0.4
(n = 79) Node Positive	27.6 ± 3.7		83.2 ± 7.1
2-Year Survival (months)
(n = 92) ≤ median value	21.8 ± 0.61	0.008	N/A	N/A
(n = 95) ≥ median value	18.8 ± 0.8
Overall Survival (months)
(n = 99) ≥ median value	47.4 ± 3.8		58.5 ± 3.6 months
(n = 98) ≤ median value	54.2 ± 3.2	0.2	52.2 ± 3.7 months	0.32
COX-2/TXS Combined Overall Survival (months)
(n = 22) High COX-2/Low TXS	N/A	N/A	45.5 ± 7.9 months	0.38
(n = 51) High COX-2/High TXS			54.1 ± 5 months

Expression profile of COX-2 and TXS in a 204-patient NSCLC TMA: correlation with clinical parameters. Expression levels of COX-2 and TXS in NSCLC TMAs were correlated with a range of clinical parameters, including patient demographics, tumour classifications and overall survival.

ISSN: 1476-4598